Combined treatment of ulinastatin and tranexamic acid provides beneficial effects by inhibiting inflammatory and fibrinolytic response in patients undergoing heart valve replacement surgery

Heart Surgery Forum

Volumn 16, Issue 1, 2013, Pages

  Chen, Ting Ting ^a   Jiandong Liu, ^b   Wang, Gang ^a   Jiang, Sheng Li ^a   Li, Li Bing ^a   Gao, Chang Qing ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 7; D DIMER; INTERLEUKIN 6; LEUKOCYTE ELASTASE; OXYGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN; VASOACTIVE AGENT;

ADULT; AGED; ANESTHESIA INDUCTION; ANTIINFLAMMATORY ACTIVITY; AORTA CLAMPING; ARTERIAL BLOOD; ARTICLE; BLEEDING; BLOOD LEVEL; BODY SURFACE; CARDIOPULMONARY BYPASS; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FIBRINOLYSIS; HEART RATE; HEART VALVE REPLACEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OXYGEN SATURATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; SURGICAL PATIENT;

ANTI-INFLAMMATORY AGENTS; ANTIFIBRINOLYTIC AGENTS; CHINA; COMORBIDITY; DRUG THERAPY, COMBINATION; GLYCOPROTEINS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INFLAMMATION; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK ASSESSMENT; TRANEXAMIC ACID; TREATMENT OUTCOME; TRYPSIN INHIBITORS;

EID: 84876267135     PISSN: 10983511     EISSN: 15226662     Source Type: Journal    
DOI: 10.1532/HSF98.20121072     Document Type: Article

References (35)

1. Aihara T, Shiraishi M, Hiroyasu S, et al. 1998. Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by downregulating TNF-alpha in the liver. Transplant Proc 30:3732-4.
2. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. 2001. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 15:101-5.
3. Bingyang J, Jinping L, Mingzheng L, Guyan W, Zhengyi F. 2007. Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularisation. Effect of ulinastatin on inflammatory response. J Cardiovasc Surg 48:497-503.
4. Cao ZL, Okazaki Y, Naito K, Ueno T, Natsuaki M, Itoh T. 2000. Ulinastatin attenuates reperfusion injury in the isolated blood-perfused rabbit heart. Ann Thorac Surg 69:1121-6.
5. Chandler WL, Fitch JC, Wall MH, et al. 1995. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 74:1293-7.
6. Chandler WL, Velan T. 2004. Plasmin generation and D-dimer formation during cardiopulmonary bypass. Blood Coagul Fibrinolysis 15: 583-91.
7. Despotis GJ, Avidan MS, Hogue CW Jr. 2001. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 72:S1821-31.
8. Endo S, Inada K, Yamashita H, et al. 1993. The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and interleukin 8. Res Commun Chem Pathol Pharmacol 82:27-34.
9. Giomarelli P, Scolletta S, Borrelli E, Biagioli B. 2003. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg 76:117-23.
10. Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. 2003. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 126:1498-503.
11. Hall TS, Sines JC, Spotnitz AJ. 2002. Hemorrhage related reexploration following open heart surgery: the impact of pre-operative and post-operative coagulation testing. Cardiovasc Surg 10:146-53.
12. Havel M, Teufelsbauer H, Knöbl P, et al. 1991. The effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 101:968-72.
13. Hirose J, Ozawa T, Miura T, et al. 1998. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 21:651-6.
14. Hunt BJ, Parratt RN, Segal HC, Sheikh S, Kallis P, Yacoub M. 1998. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 65:712-8.
15. Jimenez Rivera JJ, Iribarren JL, Raya JM, et al. 2007. Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study. J Cardiothorac Surg 2:17.
16. Karkouti K, Wijeysundera DN, Yau TM, et al. 2010. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 110:21-9.
17. Karkouti K, Wijeysundera DN, Yau TM, et al. 2004. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 44:1453-62.
18. Kluft C. 1992. Fibrinolysis and extracorporeal circulation. Agents Actions Suppl 38:305-9.
19. Koch CG, Li L, Duncan AI, et al. 2006. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg 81:1650-7.
20. Komori M, Takada K, Tomizawa Y, Uezono S, Ozaki M. 2003. Urinary trypsin inhibitor improves peripheral microcirculation and bronchospasm associated with systemic anaphylaxis in rabbits in vivo. Shock 20:189-94.
21. Kuitunen A, Hiippala S, Vahtera E, Rasi V, Salmenperä M. 2005. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery. Acta Anaesthesiol Scand 49:1272-9.
22. Lu JC, Grayson AD, Jha P, Srinivasan AK, Fabri BM. 2003. Risk factors for sternal wound infection and mid-term survival following coronary artery bypass surgery. Eur J Cardiothorac Surg 23:943-9.
23. Massoudy P, Zahler S, Becker BF, Braun SL, Barankay A, Meisner H. 2001. Evidence for inflammatory responses of the lungs during coronary artery bypass grafting with cardiopulmonary bypass. Chest 119:31-6.
24. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O'Connor GT, Dacey LJ. 1999. Is epsilon-aminocaproic acid as effective as apotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 99:81-9.
25. Nakahama H, Obata K, Sugita M. 1996. Ulinastatin ameliorates acute ischemic renal injury in rats. Ren Fail 18:893-8.
26. Nakanishi K, Takeda S, Sakamoto A, Kitamura A. 2006. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 34:1351-7.
27. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. 2001. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 69:241-7.
28. Ren B, Wu H, Zhu J, et al. 2006. Ulinastatin attenuates lung ischemia-reperfusion injury in rats by inhibiting tumor necrosis factor alpha. Transplant Proc 38:2777-9.
29. Sablotzki A, Friedrich I, Mühling J, et al. 2002. The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions. Perfusion 17:103-9.
30. Santos AT, Splettstosser JC, Warpechowski P, Gaidzinski MM. 2007. Antifibrinolytics and cardiac surgery with cardiopulmonary bypass [in Portuguese]. Rev Bras Anestesiol 57:549-64.
31. Sato Y, Ishikawa S, Otaki A, et al. 2000. Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury. Jpn J Thorac Cardiovasc Surg 48:428-34.
32. Slaughter TF, Faghih F, Greenberg CS, Leslie JB, Sladen RN. 1997. The effects of epislon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 85:1221-6.
33. Sugita T, Watarida S, Katsuyama K, Nakajima Y, Yamamoto R, Mori A. 2002. Effect of a human urinary protease inhibitor (Ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass. J Cardiovasc Surg 43:437-40.
34. Taylor NE, O'Brien S, Edwards FH, Peterson ED, Bridges CR. 2005. Relationship between race and mortality and morbidity after valve replacement surgery. Circulation 111:1305-12.
35. Wan S, LeClerc JL, Vincent JL. 1997. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 112: 676-92.